Cancer Prevention & Research Institute of Texas
Dan Hargrove, JD, LLM

Dan Hargrove, JD, LLM

Co-Founder and Past President, Cancer Insight, LLC (now LumaBridge)
CPRIT Product Development Advisory Committee Member

Dan Hargrove, JD, LLM, is a biotech entrepreneur, investor, and lawyer. Mr. Hargrove is Co-founder and past President of Cancer Insight, LLC (now LumaBridge), which is a full-service clinical Contract Research Organization that develops immunotherapeutics. Mr. Hargrove led Cancer Insight from founding to acquisition by the private equity firm Summit Partners in 2021. He is the Co-founder of PalloV, LLC, a clinical-stage drug company developing novel immunotherapeutics. Mr. Hargrove is the former CEO of Emtora Biosciences where he led the company’s efforts to translate its lead drug candidate from the bench to its first-in-human clinical trial; earned a multimillion-dollar investment from CPRIT, which was matched by private investors; obtained orphan drug designation from FDA for its lead drug candidate; and commenced a phase II study in the rare disease of familial adenomatous polyposis (ongoing). Emtora Biosciences is soon to commence its first registrational study and recently was awarded $17.7 Million from CPRIT.

Mr. Hargrove was the founding member and first investor of, Inc. Slope has created a sophisticated clinical trial execution platform that provides a systematic, real-time solution for complete visibility of clinical supply progress for sponsors, CROs, clinical research sites, and labs — all in one central location. In 2021, NEA invested $20 million into Slope. He serves on Slope’s Board of Directors and Business Advisory Board, and also serves on a handful of advisory boards for early-stage oncology companies. Mr. Hargrove serves as a member of CPRIT’s Product Development Advisory Committee and the External Advisory Committee for the Texas Medical Center – Accelerator for Cancer Therapeutics.

Mr. Hargrove is a former active-duty U.S. Army officer, having served with the 10th Mountain Division (Light Infantry) and deployed to the Middle East with the 82nd Airborne Division. As a reservist, he served as a Professor of Law at the U.S. Army JAG School from 2004 to 2012 and reserve Staff Judge Advocate (general counsel) of two major commands. He retired from the military Reserve in 2018 with the rank of Lieutenant Colonel. 

Copyright © 2024 Cancer Prevention and Research Institute of Texas